Myriad Genetics, Inc.

MYGN

$19.49

-44.5% last 12 months

Steven Cohen Holding value: $4.47 Million Jim Simons Holding value: $1.82 Million Ken Fisher Holding value: $1.4 Million Jeremy Grantham Holding value: $0 Ken Griffin Holding value: $0 Joel Greenblatt Holding value: $0 Jeffrey Ubben Holding value: $0 Mario Gabelli Holding value: $0 Tiger Global Holding value: $0 George Soros Holding value: $0

Market Cap

$1.54 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$16.02 - $34.95

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

-87.69x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $1.54 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. $1.34 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $0.00 (0.0%)
1 Year Return Profit or loss of share price change plus dividend yield. -44.5%
52-Week High Highest share price in the last 52 weeks. $34.95
52-Week Low Lowest share price in the last 52 weeks. $16.02
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 1.41
Outstanding Shares The number of shares the company has issued and are held by stockholders. 80.6 Million
Avg 30 Day Volume The number of shares traded in the last 30 days. 467 Thousand

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. -87.69
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. -43.85
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. -$0.22
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 2.44
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 1.77
Enterprise Value to Revenue Enterprise value divided by revenue 1.99
Enterprise Value to EBIT Enterprise Value divided by EBIT -14.09
Total Debt to Enterprise Value Total debt divided by enterprise value 0.0
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 0.0

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. $672 Million
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. $481 Million
EBIT Earnings before tax and interest payments. -$95 Million
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. -$17.6 Million
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. -2.62%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. +200.0%
Return on Equity Equity divided by market cap. -1.86%
Return on Assets Indicates a company's profitability in relation to its total assets. -1.45%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. -8.71%

Insider trades

No purchases

1,420.0 shares sold (1 transactions)

No purchases

No sells

No purchases

No sells

No purchases

No sells

Q4 2021 Q1 2022 Q2 2022 Q3 2022

About Myriad Genetics, Inc.

CEO: R. Bryan Riggsbee

Employees: 2,600

Industry: Pharmaceutical Preparation Manufacturing

Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.

Similar stocks

Bio-Rad Laboratories Inc. - Class A
Bio-Rad Laboratories Inc. - Class A
Exact Sciences Corp.
Exact Sciences Corp.
Biocept Inc
Biocept Inc
Biomarin Pharmaceutical Inc. - Registered Shares
Biomarin Pharmaceutical Inc. - Registered Shares
Abbott Laboratories
Abbott Laboratories

News

Myriad Stock: Trying To Find Its Footing In An Evolving Industry (NASDAQ:MYGN)

Myriad Stock: Trying To Find Its Footing In An Evolving Industry (NASDAQ:MYGN)

Myriad Genetics is a leading provider of genetic testing services and products. See prudent investors might want to pass on MYGN stock.

Seeking Alpha Seeking Alpha, 4 days ago
Myriad Genetics, Inc.: New Study Published in Clinical Cancer Research Journal Highlights Use of EndoPredict Test to Inform Treatment for Premenopausal Breast Cancer Patients

Myriad Genetics, Inc.: New Study Published in Clinical Cancer Research Journal Highlights Use of EndoPredict Test to Inform Treatment for Premenopausal Breast Cancer Patients

Myriad Genetics'' EndoPredict test accurately identified premenopausal women with ER+, HER2- breast cancer who could safely avoid adjuvant chemotherapy SALT ...

Finanz Nachrichten Finanz Nachrichten, 29 days ago
Myriad Genetics Gets Expanded Coverage for BRACAnalysis CDx in Japan

Myriad Genetics Gets Expanded Coverage for BRACAnalysis CDx in Japan

Testing will be reimbursed for patients with early-stage breast cancer to guide adjuvant treatment with the PARP inhibitor Lynparza.

GenomeWeb GenomeWeb, about 1 month ago
Myriad Genetics receives expanded coverage in Japan for breast cancer diagnostic system

Myriad Genetics receives expanded coverage in Japan for breast cancer diagnostic system

Myriad Genetics (MYGN) said on Thursday that Japan’s Ministry of Health, Labour and Welfare ((MHLW)) had granted expanded coverage for the use of its BRACAna...

Seeking Alpha Seeking Alpha, about 1 month ago
Never miss a trade
To improve your user experience we use cookies.